An Intensive Advanced Workshop on Evolving Strategies in Hepatitis C Management
Monday, March 9, 2015
1:00 PM – 5:00 PM
Assessment of Needs
Rapid advances in HCV disease management require the ongoing attention of practitioners involved in HCV medicine. This workshop will address the implications of new information on strategies for clinical management. Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of HCV clinicians and researchers.
The workshop will address the following issues:
- Current data on new drugs for HCV
- Practical issues in HCV management
- Treatment of patients with HIV/HCV coinfection
On completion of the activity, participants will be able to:
- Describe currently available HCV treatment regimens and list the investigational drugs and drug classes that are advancing in clinical trials
- List current therapeutic options for patients in whom treatment has started
- List the advantages and disadvantages of the differing approaches to staging liver disease in HCV-infected patients
- Describe treatment modifications for patients who require special considerations, including patients with cirrhosis; post-transplant patients; patients with renal insufficiency; patients with acute HCV infection; and patients with HCV/HIV coinfection
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Who Should Attend
This intensive half-day workshop is limited to no more than 35 clinical decision makers (physicians, nurse practitioners, pharmacists, and physician assistants). Individuals may register for only 1 of the workshops in each city, either Introductory or Advanced. The small-group, interactive format is designed for physicians who have a good understanding of the basics of HCV transmission, testing, and management, and have managed HCV infection in at least 5 patients.
Representatives and employees of commercial companies (pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms, etc) must contact the IAS–USA regarding registration procedures.
Cancellation and substitution requests must be made 8 or more days before the date of an activity. All refunds will be processed a week after the workshop minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the workshop will not be eligible for the partial refund.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 3.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Education Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 3.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 3.5 hours (0.35 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-15-075-L01-P
This workshop is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Merck & Co, Inc